报价延迟最少15分钟:2025/08/18 02:11 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.2 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-42.65/-14.40
|
|
企业价值
38.20M
|
| 资产负债 |
|
每股账面净值
-1.73
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
57.34K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/08/18 02:11 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Hyperion DeFi Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of noveland existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or New combinations. |
